Evox Therapeutics

Evox Therapeutics is a private, pre-clinical stage biotech founded in 2016 and headquartered in Oxford, UK. The company is developing a novel therapeutic platform, ExoEdit®, which leverages engineered exosomes to deliver proprietary gene editors to the brain, aiming to address the root cause of genetically-driven neurodegenerative diseases. Its strategy involves building a pipeline based on human genetic data and preclinical validation while actively seeking strategic partnerships to advance its mission. Recent activities include a collaboration with the Rett Syndrome Research Trust and strengthening its governance with key board and advisory appointments.

ExoEdit® platform: an exosome-based delivery system engineered to carry a proprietary CRISPR-based gene editor for targeted delivery to the central nervous system, designed to enhance safety, potency, and brain access compared to current technologies.

Evox competes in the crowded and rapidly evolving field of genetic medicine delivery to the CNS. Key competitors include companies using engineered AAV vectors (e.g., Voyager Therapeutics, Lexeo Therapeutics) and those developing non-viral delivery methods like lipid nanoparticles. Other biotechs are also exploring exosome-based delivery, making technological differentiation and robust preclinical data critical for Evox to stand out.